July 2026 in “JAAD reviews.” GLP-1 receptor agonists may cause hair loss, but more research is needed.
September 2025 in “Cureus” GLP-1 agonists may help treat certain skin conditions.
54 citations
,
December 2007 in “Best Practice & Research Clinical Endocrinology & Metabolism” Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.
May 2026 in “Open Access CRIS of the University of Bern” GLP-1 receptor agonists can both help and harm hair, so careful monitoring is needed.
1 citations
,
May 2025 in “Cell Reports Medicine” RSPO1 could help create new diabetes treatments by increasing pancreatic β cells.
11 citations
,
August 2020 in “Diabetes” Testosterone helps human pancreatic cells increase insulin release.
July 2025 in “International Journal of Dermatology”
July 2026 in “Journal of the American Academy of Dermatology” GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.
June 2017 in “Acta Scientiae Veterinariae” A cat with a rare pancreatic tumor and diabetes died despite treatment, showing similar symptoms to a human condition.
Improved nutrition quickly healed the patient's skin lesions.
4 citations
,
December 1962 in “European journal of endocrinology” Alloxan diabetes, methylthiouracil, cortisone, and adrenaline affect how white mice hair follicles use glucose and cystine and their cell division.
June 2026 in “Frontiers in Nutrition” GLP-1 receptor agonists can help manage PCOS metabolism but need careful use before conception.
April 2026 in “Open MIND” GLP-1 medications can cause skin and muscle issues, but treatments like ultrasound and PRP can help.
May 2024 in “International Journal of Dermatology” More research is needed to understand if GLP-1 agonists affect hair health.
February 2026 in “Pediatrics in Review” A newborn with severe low blood sugar due to a genetic issue needed major surgery after standard treatments failed.
31 citations
,
January 2025 in “Journal of the American Academy of Dermatology” GLP-1 RA medications may be linked to hair loss.
September 2025 in “Wound Repair and Regeneration” GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
1 citations
,
June 2001 in “Annals of Internal Medicine” Troglitazone increases subcutaneous fat in lipodystrophy patients.
Testosterone in human pancreas cells boosts insulin production.
24 citations
,
April 2008 in “Fertility and sterility” Pioglitazone improved insulin sensitivity and altered cortisol metabolism in PCOS patients.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
May 2026 in “Dermatologic Surgery” GLP-1RAs may cause hair loss but could also help regrow hair in some cases.
Testosterone in our bodies helps increase insulin secretion from the pancreas.
GLP-1 receptor agonists increase the risk of hair loss, mainly due to weight loss-related nutrient deficiency.
April 2026 in “American Journal of Clinical Dermatology” GLP-1 receptor agonists may help or harm hair health, needing more research.
March 2026 in “Journal of Pharmaceutical Research” Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
GLP-1 receptor agonists increase the risk of hair loss, mainly due to nutrient deficiency from weight loss.
13 citations
,
February 2016 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Mice without active or present vitamin D receptors maintain normal blood sugar control and islet gene expression when calcium levels are normal.
October 2024 in “Irish Journal of Medical Science (1971 -)” Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.